Bristol Will Leap 'Over Its Patent Cliff,' In 2013, Sigal Tells Investors
This article was originally published in The Pink Sheet Daily
Executive Summary
With a dozen approvals in the past eight years, the company believes it has "eradicated" its patent cliff and is looking at a significant growth cycle.
You may also be interested in...
Xarelto Faces Approval, Labeling Obstacles Even After Cmte. Endorsement
Bayer and Johnson & Johnson may have won the battle in securing an FDA advisory committee endorsement of Xarelto (rivaroxaban) for atrial fibrillation, but they may well lose the war of the novel anticoagulants given the panel’s unfavorable labeling recommendations if the oral Factor Xa inhibitor is approved.